Since 2017, Angelini Pharma and TEHA worked collaboratively on the Headway Initiative: a platform promoting reflection, analysis, dialogue and comparison in the management of Brain Health across Europe.
Epilepsy is a chronic condition that affects millions of people globally.1 It is characterized by the recurrence of epileptic seizures, usually of short duration, lasting from seconds to a few minutes.
Epilepsy is one of the most common neurological conditions and is characterized by a predisposition to spontaneous seizures. What are seizures and what is the impact of this disease on patients?
Epilepsy is a complex neurological disorder that manifests itself in a range of forms, to the extent that it is more accurate to speak of “epilepsies” in the plural rather than singular.
Epilepsy is a chronic neurological disease, often associated with numerous comorbidities. Can having epilepsy increase the risk of COVID-19 infection or progression to severe COVID-19? How has the pandemic affected people with epilepsy?
Epilepsy is a chronic neurological disease that can have a major impact on the various stages of a woman's life. How does the course of this disease evolve from puberty to menopause?
The ketogenic diet is a dietary regimen characterized by a high lipid content and reduced carbohydrate and protein intake.
Research presented in Brussels by Angelini Pharma and The European House - Ambrosetti highlights that one in two young Europeans report unmet needs for mental healthcare.
Every year, on October 10th, World Mental Health Day provides a great opportunity to increase awareness on mental health issues and underline the necessity of addressing these challenges on a global scale.
Research presented in Rome by Angelini Pharma and The European House - Ambrosetti highlights that almost 40% of people with epilepsy receive inadequate treatment.
Harmonia Mentis Global